<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1401594</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1401594</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hyaluronic acid-solid lipid nano transporter serum preparation for enhancing topical tretinoin delivery: skin safety study and visual assessment of skin</article-title>
<alt-title alt-title-type="left-running-head">Mehmood et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1401594">10.3389/fphar.2024.1401594</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mehmood</surname>
<given-names>Yasir</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2055557/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shahid</surname>
<given-names>Hira</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rizvi</surname>
<given-names>Syeda Momena</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2829990/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jamshaid</surname>
<given-names>Usama</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arshad</surname>
<given-names>Numera</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nur-e-Alam</surname>
<given-names>Mohammad</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hussain</surname>
<given-names>Muhammad Delwar</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kazi</surname>
<given-names>Mohsin</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/511415/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Riphah Institute of Pharmaceutical Sciences (RIPS)</institution>, <institution>Riphah International University Faisalabad</institution>, <addr-line>Faisalabad</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pharmacology</institution>, <institution>Faculty of Pharmaceutical Sciences</institution>, <institution>Government College University Faisalabad</institution>, <addr-line>Faisalabad</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Biochemistry</institution>, <institution>University of Agriculture</institution>, <addr-line>Faisalabad</addr-line>, <addr-line>Punjab</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Faculty of Pharmaceutical Sciences</institution>, <institution>University of central Punjab</institution>, <addr-line>Lahore</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Pharmacy</institution>, <institution>COMSATS University Islamabad, (Lahore Campus)</institution>, <addr-line>Islamabad</addr-line>, <country>Pakistan</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Pharmacognosy</institution>, <institution>College of Pharmacy</institution>, <institution>King Saud University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Department of Pharmaceutical Sciences</institution>, <institution>School of Pharmacy</institution>, <institution>University of Maryland Eastern Shore</institution>, <addr-line>Princess Anne</addr-line>, <addr-line>MD</addr-line>, <country>United States</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>Department of Pharmaceutics</institution>, <institution>College of Pharmacy</institution>, <institution>King Saud University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/485147/overview">Chandraiah Godugu</ext-link>, National Institute of Pharmaceutical Education and Research, India</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1683434/overview">Imran Shair Mohammad</ext-link>, City of Hope National Medical Center, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1297540/overview">Nagavendra Kommineni</ext-link>, Population Council, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yasir Mehmood, <email>yasirmehmoodamjad@gmail.com</email>; Mohsin Kazi, <email>mkazi@ksu.edu.sa</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1401594</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Mehmood, Shahid, Rizvi, Jamshaid, Arshad, Nur-e-Alam, Hussain and Kazi.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Mehmood, Shahid, Rizvi, Jamshaid, Arshad, Nur-e-Alam, Hussain and Kazi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The use of nanosized particles is becoming more popular for the topical treatment of skin conditions. In this research work, we created and investigated the effects of solid lipid nanoparticles (SLN) containing hyaluronic acid and tretinoin. Solvent emulsification diffusion method was used to prepare the SLN formulation and characterized for their physicochemical properties. Fourier transform infrared spectroscopy was used to confirm that hyaluronic acid and tretinoin were incorporated in the SLN. Furthermore, X-ray diffractogram, thermal analysis including DSC and TGA and <italic>in vitro</italic> dissolution, permeation tests were also performed along with microbial assessment. Clinical studies in human were performed to evaluate the effect of the SLN on skin wrinkles. The SLN was 750 &#xb1; 31.29&#xa0;nm in size, with a zeta potential of 13.07 &#xb1; 0.75&#xa0;mV and a narrow polydispersity index of 0.24 &#xb1; 0.12. The entrapment efficiency of tretinoin was found to be 90.07 <inline-formula id="inf1">
<mml:math id="m1">
<mml:mrow>
<mml:mo>&#xb1;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> 4.79%. Clinical studies in healthy human volunteers demonstrated that 90% of the tested individuals had improved skin conditions (reduction in wrinkles), by at least one grade after 4&#xa0;weeks of treatment. Regarding the development on SLN, it was found that the internal phase concentration did not considerably affect the physicochemical and microbiological properties. Therefore, Hyaluronic acid has potential for the development of SLN applicable to cosmetic formulations, especially for skin. These findings show that the developed SLN have potential for use as cosmetics in the future.</p>
</abstract>
<kwd-group>
<kwd>hyaluronic acid</kwd>
<kwd>filler</kwd>
<kwd>topical</kwd>
<kwd>solvent</kwd>
<kwd>diffusion</kwd>
<kwd>tretinoin</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Experimental Pharmacology and Drug Discovery</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Tretinoin (TR), also known as all-trans retinoic acid, is a vitamin A metabolite used topically to treat a variety of skin conditions, including acne and wrinkles or skin aging (<xref ref-type="bibr" rid="B42">Zasada and Budzisz, 2019</xref>; <xref ref-type="bibr" rid="B38">Szyma&#x144;ski et al., 2020</xref>; <xref ref-type="bibr" rid="B32">Riahi et al., 2016</xref>). However, a number of drawbacks, including skin irritability and high chemical instability, restrict its application (<xref ref-type="bibr" rid="B30">Raminelli et al., 2018</xref>; <xref ref-type="bibr" rid="B12">Keeling et al., 2008</xref>). Tretinoin, chemically named (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona2,4,6,8-tetraenoic acid, is a dermatological agent. It is found as a yellow or light orange crystalline powder that is only slightly soluble in alcohol and nearly insoluble in water. In particular, it is sensitive to heat, light, and oxygen when in solution. It decomposes and melts at roughly 182&#x2103;. The chemical formula of tretinoin is C<sub>20</sub>H<sub>28</sub>0<sub>2</sub>, and its molecular mass is 300.44&#xa0;g&#xa0;mol<sup>&#x2212;1</sup>.</p>
<p>Topical therapy of skin conditions seems preferable due to the lower likelihood of systemic side effects (<xref ref-type="bibr" rid="B34">Sch&#xe4;cke et al., 2009</xref>; <xref ref-type="bibr" rid="B35">Sch&#xe4;fer-Korting et al., 2007</xref>). However, the stratum corneum prevents xenobiotics from penetrating living skin, and only a small percentage of the applied medication can be absorbed. Dermal penetration can be increased by using particle carrier systems (<xref ref-type="bibr" rid="B29">Prow et al., 2011</xref>). Skin lipids play a significant role in the penetration barrier and lipid carriers that could facilitate lipid exchange with the skin&#x2019;s surface (<xref ref-type="bibr" rid="B43">Zhai and Zhai, 2014</xref>). Lipid microspheres, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLCs), liposomes, microemulsions and hexagonal phase nanodispersions are some examples of carrier systems for skin surfaces (<xref ref-type="bibr" rid="B25">M&#xfc;ller et al., 2002</xref>; <xref ref-type="bibr" rid="B24">Montenegro et al., 2016</xref>). For topical SLN, all excipients used in current topical cosmetic and dermal pharmaceutical products can be used (<xref ref-type="bibr" rid="B25">M&#xfc;ller et al., 2002</xref>). There are several cosmetic product are now marketed with nano technology (<xref ref-type="bibr" rid="B9">Jose and Netto, 2019</xref>).</p>
<p>In fact, the type of lipid particle and the way that drugs interact with the lipid matrix were found to be important. Drug skin penetration can be improved by SLN. SLN can also cause epidermal targeting, particularly when the drug is at the particle surface. In this study we have used TR for wrinkles treatment along with Hyaluronic acid (HA). HA is a naturally occurring polymer composed of unbranched repeating units of glucuronic acid and N-acetyl glucosamine linked by 1&#x2013;3 and 1&#x2013;4 glycosidic bonds (<xref ref-type="bibr" rid="B14">Kong et al., 2011</xref>). HA is a biopolymer that has found extensive usage in the pharmaceutical industry due to its array of intriguing characteristics, including bioadhesion (ability to stick to negatively charged surfaces such as skin and mucosa). It is a part of the extracellular matrix and is also found in connective, epithelial, and brain tissues. Hyaluronic acid serves as a skin conditioner and/or a viscosity modifier in cosmetic compositions. HA is mostly found in anti-aging cosmetics (<xref ref-type="bibr" rid="B10">Juncan et al., 2021</xref>). HA is still a relatively new chemical compound of treating wrinkles and lines on the face, and it has already made significant strides in the field of cosmetic surgery. Hyaluronic acid fillers have been given the go-ahead by the Food and Drug Administration, as well as their current use in facial cosmetics (<xref ref-type="bibr" rid="B22">Monheit and Coleman, 2006</xref>). Under physiological circumstances, HA may also work in the skin as an antioxidant and free radical scavenger (<xref ref-type="bibr" rid="B27">Pavicic et al., 2011</xref>). To enhance contact and internalization in ocular cells, solid lipid nanoparticles have been combined with HA. The bioadhesive ability of HA can improve drug retention at the application site.</p>
<p>In this project, transdermal administration of SLN with HA and TR (H-T-SLN) was studied for biological applications to treat wrinkles. Due to the synergistic effects of the following elements, HA may be the essential component that helps Nano constructs penetrate the skin more effectively. The hygroscopic HA molecules moisten skin tissues and enable conjugated cargoes to go through the skin transdermally. In this research, we used HA as SLN vehicle and it is most promising material for skin therapeutic purposes.</p>
<p>We aimed to prepare HA and tretinoin-associated SLN. The nanoparticle size, zeta potential, polydispersity index (PDI), association efficacy, loading efficacy, structural confirmation, shape and safety are among its many physicochemical properties. A range of biophysical approaches can be used to objectively and noninvasively measure the ageing of the skin in response to topical treatments. Moreover, we prepared serum by using loaded SLN for customer use and examined human skin by using a camera Visioscan<sup>&#xae;</sup> camera. In the current investigation, a 4-week phase II single controlled group, before-after clinical study was developed and investigated to determine the anti-wrinkle impact of a topical H-T-SLN serum comprising HA and tretinoin on a variety of skin aging endpoints.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Chemicals</title>
<p>Saffron Pharmaceuticals gratefully offered tretinoin (Faisalabad, Pakistan). Dialysis membranes with a molecular weight cut-off (MWCO) of 8,000&#xa0;Da were purchased from Spectrum Medical Industries (Houston, Texas, United States). Dae-Jung (City, Korea) chemicals were used to obtain ethanol, glycerin, propylene glycol, polylobate 80, cetostearyl alcohol and hyaluronic acid. We purchased hyaluronic acid from Merck (CAS No.: 9012-76-4). 2-Phenylethanol (Epikuron) was purchased from Lucas Meyer (Hamburg, Germany). Double-distilled water produced at a nearby plant was utilized throughout the trials and conductivity of water was (2.1&#xa0;<italic>&#x3bc;s/cm</italic>
<sup>2</sup>). All of the other chemicals and solvents were analytical grade, and we used them exactly as they were provided.</p>
</sec>
<sec id="s2-2">
<title>Preparation of SLN</title>
<p>The solvent emulsification diffusion method was used to create SLN. Emulsifiers (cetostearyl alcohol) were dispersed in 10&#xa0;mL distilled water with magnetic stirring at 50<inline-formula id="inf2">
<mml:math id="m2">
<mml:mrow>
<mml:mo>&#x2103;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>. After 15&#xa0;min, ethanol was added dropwise to this dispersion (10&#xa0;g). Ten milligrams of tretinoin was mixed by continuous stirring. This is known as Phase I (oil phase). Phase II (water phase) was prepared by adding hyaluronic acid in water (15&#xa0;mL). After 30&#xa0;min of continuous stirring, Tween 80 and 2-phenylethanol (fragrance agent) were added in this water phase. After this, phase I (oil phase) was added into phase II (water phase) by using a 24 gauge needle syringe and probe sonicator (JY92-2D; Xinzhi Equ. Inst., China) (300&#xa0;W). The probe was sonicated for 20&#xa0;min at 40% amplitude and then homogenized for 5&#xa0;min at 12,000&#xa0;rpm. Hyaluronic acid tretinoin SLN (H-T-SLN) were filtered through a 0.45&#xa0;<italic>&#x3bc;</italic>m membrane to eliminate impurity materials (such as metal) introduced during ultrasonication, and then 10.86% glycerin and 5.43% propylene glycol were added for the formation of serum. This project was completed in a saffron pharmaceuticals industry, and saffron-developed plant capabilities allow us to support large-scale manufacturing. During lab-scale preparation, we also determined critical quality attributes and critical process parameters, which were monitored at the scale-up. Optimized formulation mentioned in <xref ref-type="table" rid="T1">Table 1</xref> with percentage of ingredients. Optimised process for preparing mentioned in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Optimized formulation of the product.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Sr. &#x23;</th>
<th align="left">Material name</th>
<th align="left">Quantity (g) of material</th>
<th align="left">Percentage (%) of material</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">Hyaluronic acid</td>
<td align="center">0.5</td>
<td align="center">1.1</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Tretinoin</td>
<td align="center">0.01</td>
<td align="center">0.02</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">Cetostearyl alcohol</td>
<td align="center">0.5</td>
<td align="center">1.1</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Ethanol</td>
<td align="center">10</td>
<td align="center">21.73</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">2-Phenylethanol</td>
<td align="center">2.5</td>
<td align="center">5.43</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Water</td>
<td align="center">25</td>
<td align="center">54.34</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">Propylene glycol</td>
<td align="center">2.5</td>
<td align="center">5.43</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">Glycerin</td>
<td align="center">5</td>
<td align="center">10.86</td>
</tr>
<tr>
<td colspan="2" align="center">Total</td>
<td align="center">46.01</td>
<td align="center">100</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>2-Phenyethanol.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>
<italic>Preparation method of</italic> H-T-SLN serum is mentioned Phase I (oil phase) and Phase II (water phase).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g001.tif"/>
</fig>
</sec>
<sec id="s2-3">
<title>Determination of entrapment efficiency</title>
<p>Hyaluronic acid tretinoin SLN (H-T-SLN) serum precipitation was performed by centrifuging 1&#xa0;mL of loaded tretinoin nanodispersion in dichloromethane at 2,000&#xa0;rpm for 15&#xa0;min. The supernatant was discarded, and 500&#xa0;<italic>&#x3bc;L</italic> dichloromethane was used to dissolve the silt containing tretinoin. Carry out the procedure in subdued light. The material was centrifuged for 15&#xa0;min (30&#x2103;), and dichloromethane was added to a volume of 50&#xa0;mL. Again, 3&#xa0;mL of solution was diluted to 100&#xa0;mL with a solution (prepared by diluting 5&#xa0;mL of 0.1&#xa0;M hydrochloric acid to 250&#xa0;mL with 96% ethanol) and filtered with 0.2&#xa0;<italic>&#x3bc;m</italic> Sartorius. The absorbance of this solution was measured at a maximum of 295&#xa0;nm using ethanolic hydrochloric acid solution as a blank. The content of tretinoin was calculated by taking 1,350 as the value of a (1% 1&#xa0;cm) (Quartz cells) at 295&#xa0;nm. The acquired absorbance was compared to the standard, and a triplicate calculation of the drug loading efficiency was made. <xref ref-type="disp-formula" rid="e1">Equation 1</xref> was used to determination of entrapment efficiency of particles (<xref ref-type="bibr" rid="B11">Karami and Abdouss, 2024</xref>; <xref ref-type="bibr" rid="B41">Yang et al., 2024</xref>).<disp-formula id="e1">
<mml:math id="m3">
<mml:mrow>
<mml:mtext mathvariant="bold">Entrapment&#x2009;</mml:mtext>
<mml:mtext mathvariant="bold">efficiency&#x2009;</mml:mtext>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi mathvariant="bold-italic">D</mml:mi>
<mml:mi mathvariant="bold-italic">r</mml:mi>
<mml:mi mathvariant="bold-italic">u</mml:mi>
<mml:mi mathvariant="bold-italic">g</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="bold-italic">a</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mi mathvariant="bold-italic">e</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="bold-italic">F</mml:mi>
<mml:mi mathvariant="bold-italic">r</mml:mi>
<mml:mi mathvariant="bold-italic">e</mml:mi>
<mml:mi mathvariant="bold-italic">e</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mi mathvariant="bold-italic">r</mml:mi>
<mml:mi mathvariant="bold-italic">u</mml:mi>
<mml:mi mathvariant="bold-italic">g</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi mathvariant="bold-italic">D</mml:mi>
<mml:mi mathvariant="bold-italic">r</mml:mi>
<mml:mi mathvariant="bold-italic">u</mml:mi>
<mml:mi mathvariant="bold-italic">g</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="bold-italic">a</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
<mml:mi mathvariant="bold-italic">e</mml:mi>
<mml:mi mathvariant="bold-italic">d</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi mathvariant="bold-italic">X</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mn mathvariant="bold">100</mml:mn>
</mml:mrow>
</mml:math>
<label>(1)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-4">
<title>Particle size, polydispersity index (PDI) and zeta potentials</title>
<p>Photon correlation spectroscopy (PCS) (Nano ZS Zetasizer, Malvern Instruments Corp, United Kingdom) was used to measure the mean diameter (Z-average diameter), polydispersity and size distribution at 25&#xb0;C in polystyrene cuvettes with a path length of 10&#xa0;mm. Using a Nano ZS Zetasizer and laser Doppler anemometry, the zeta potential was calculated. Deionized water from a Milli-Q system was used for the measurements, which were carried out in capillary cells with 10&#xa0;mm path lengths. A triple of each measurement was made (<xref ref-type="bibr" rid="B17">Mehmood et al., 2020</xref>).</p>
</sec>
<sec id="s2-5">
<title>FTIR spectroscopy</title>
<p>
<italic>A</italic> Thermo Scientific Nicolet iN5 FTIR United States with diamond ATR was used in the current experiment. A small sample was added to the apparatus with the use of a spatula, and the fixing clamp was tighter. In the 800&#x2013;4,000&#xa0;cm<sup>&#x2212;1</sup> region, this method was employed to capture the spectra of tretinoin, hyaluronic acid and hyaluronic acid tretinoin SLN (H-T-SLN) (<xref ref-type="bibr" rid="B33">Ruther, 2022</xref>).</p>
</sec>
<sec id="s2-6">
<title>Thermal analysis DSC and TGA study</title>
<p>Calorimetry experiments were carried out using DSC and TGA equipment (Mettle Toledo DSC823, Switzerland). Tretinoin, Hyaluronic acid and Hyaluronic acid Tretinoin SLN (H-T-SLN) were all measured, with an empty aluminum pan serving as the standard. In 40 <inline-formula id="inf3">
<mml:math id="m4">
<mml:mrow>
<mml:mi>&#x3bc;</mml:mi>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula> aluminum pans, 1&#x2013;2&#xa0;mg of sample was precisely weighed, and the DSC/TGA spectrum was captured while the temperature was heated at a rate of 5&#xa0;K/min from 25 to 300&#x2103;. Each experiment was carried out three times (<xref ref-type="bibr" rid="B26">Nasrollahi et al., 2013</xref>).</p>
</sec>
<sec id="s2-7">
<title>XRPD study</title>
<p>
<italic>An</italic> X-ray powder diffraction analyser manufactured by DADVANCE, Bruker, Germany was used to examine Tretinoin, Hyaluronic acid and Hyaluronic acid Tretinoin SLN (H-T-SLN). The instrument was run at 30&#xa0;kV and 15&#xa0;mA with Cu K&#x3b1; radiation (1.542&#xa0;&#xc5;) in the range of 5 to 40 2&#x3b8;. The information was then computed as peak height (intensity) versus 2&#x3b8; (<xref ref-type="bibr" rid="B16">Mehmood et al., 2019</xref>).</p>
</sec>
<sec id="s2-8">
<title>Morphology study</title>
<p>An examination of morphology was performed using a scanning electron microscope (JEOL Ltd., Tokyo, Japan). We used gold-coated dual-sided adhesive tape with dry samples, Tretinoin in crystal form and Hyaluronic acid Tretinoin SLN (H-T-SLN) were analysed (magnification: 30,000&#xd7;; accelerating voltage: 20.0&#xa0;kV). Analysis was performed at 25&#xb0;C &#xb1; 2&#xb0;C (<xref ref-type="bibr" rid="B37">Smirnova et al., 2023</xref>).</p>
</sec>
<sec id="s2-9">
<title>
<italic>In vitro</italic> release study</title>
<p>Utilizing the dialysis membrane method, <italic>in vitro</italic> research on tretinoin, hyaluronic acid and hyaluronic acid tretinoin SLN (H-T-SLN) was conducted. The SLN equivalent of 1&#xa0;mg was diluted in 5&#xa0;mL of distilled water and placed inside a dialysis bag (Spectrum Medical Industries, Houston, Texas, United States). A closed pouch was created by sealing the bag. The dialysis bag was then suspended separately in 500&#xa0;mL of medium that was kept at 37&#xb0;C with constant stirring at 50&#xa0;rpm and contained phosphate buffer with a pH of 7.4 and 0.1&#xa0;M HCl with a pH of 1.2 at different time points. The 2.0&#xa0;mL samples were taken out and refilled at the same volume from new media under the same conditions at predetermined intervals up to 60&#xa0;min. The resultant filtrate was collected through a 0.45&#xa0;m pore size filter and used for UV analysis after being diluted (<xref ref-type="bibr" rid="B44">Zhang et al., 2010</xref>). The percentage release was calculated by following <xref ref-type="disp-formula" rid="e2">Equation 2</xref> (<xref ref-type="bibr" rid="B5">Barkat et al., 2018</xref>; <xref ref-type="bibr" rid="B13">Khalid et al., 2018</xref>; <xref ref-type="bibr" rid="B18">Mehmood et al., 2023a</xref>):<disp-formula id="e2">
<mml:math id="m5">
<mml:mrow>
<mml:mi>D</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>g</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>s</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>e</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>a</mml:mi>
<mml:mi>b</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>b</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>d</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>a</mml:mi>
<mml:mi>b</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>b</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>e</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
</mml:mrow>
</mml:math>
<label>(2)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-10">
<title>Hemolytic investigations</title>
<p>Hyaluronic acid Tretinoin SLN (H-T-SLN) was mixed with rat blood to determine the hemolytic investigation. Permission was obtained from the ethical review board of Rashid Latif College of Pharmacy (RLCP) Lahore, Pakistan IRB No (RLCP/EP/28/2022). A tube containing ethylene diamine tetraacetic acid was used to collect blood for the hemolytic test, and after 5&#xa0;min of centrifugation at 1,500&#xa0;rpm, the supernatant was removed, while the precipitate was washed three times with phosphate-buffered saline (PBS). Then, 200&#xa0;<italic>&#x3bc;L</italic> of washed blood was mixed with 3.8&#xa0;mL of phosphate-buffered saline and vortexed for a while. The mixture was centrifuged at 1,600&#xa0;rpm for 5&#xa0;min after the samples were kept at 37&#xb0;C for 2&#xa0;h. Measure the absorbance of the supernatant at 541&#xa0;nm. In this experiment, phosphate-buffered saline was chosen as the negative control, and Triton-X was chosen as the positive control. The malformation of blood cells was observed through microscopy (not shown in article), and % hemolysis was determined by using <xref ref-type="disp-formula" rid="e3">Equation 3</xref> (<xref ref-type="bibr" rid="B19">Mehmood et al., 2023b</xref>; <xref ref-type="bibr" rid="B20">Mehmood et al., 2023c</xref>).<disp-formula id="e3">
<mml:math id="m6">
<mml:mrow>
<mml:mo>%</mml:mo>
<mml:mi mathvariant="italic">&#x2009;Hemolysis</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mi mathvariant="italic">ABS</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="italic">ABS</mml:mi>
<mml:mn>0</mml:mn>
<mml:mo>/</mml:mo>
<mml:mi mathvariant="italic">ABS</mml:mi>
<mml:mn>100</mml:mn>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="italic">ABS</mml:mi>
<mml:mn>0</mml:mn>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mo>&#x2217;</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
<label>(3)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-11">
<title>
<italic>In vitro</italic> diffusion studies</title>
<p>For the diffusion study of Hyaluronic acid Tretinoin SLN (H-T-SLN), Franz Diffusion Cell (local made by IPS Analytical system, Lahore, Pakistan) was used. A silicon membrane (Silatos&#x2122; 0.13&#xa0;mm silicone, Teleflex Medical, Westmeath, Ireland) was used in this experiment. The penetration of the H-T-SLN was evaluated using a vertical Franz diffusion cell with a donor surface area of 1.2&#xa0;cm<sup>2</sup> and a receptor volume of 5.2&#xa0;mL with a silicon membrane. A semisynthetic Silatos&#x2122; 0.13&#xa0;mm silicone membrane was adjusted within the donor and receptor chambers of the Franz diffusion cell. In a 1.0&#xa0;mL volume, the H-T-SLN sample was added. The temperature of the receptor chamber was maintained at 37&#xb0;C while phosphate buffer (pH 7.4) was circulated. The membrane and receptor phase were in contact for 1&#xa0;h at a temperature of 37 0.5&#xb0;C before the experiment. Samples (0.5&#xa0;mL) were taken every time for 120&#xa0;min (5, 20, 40, 60, 80, 100 and 120&#xa0;min) during the receptor phase, and 50&#xa0;mL of dichloromethane was added to the samples at predefined intervals. Once more, 3&#xa0;mL of solution was diluted in 100&#xa0;mL of solution (5&#xa0;mL of 0.1&#xa0;M hydrochloric acid in 250&#xa0;mL of 96% ethanol). Using ethanolic hydrochloric acid solution as a blank, the absorbance of this solution was measured at 295&#xa0;nm. The amount of tretinoin was determined by using the value of a (1% 1&#xa0;cm) 1,350 at 295&#xa0;nm (<xref ref-type="bibr" rid="B16">Mehmood et al., 2019</xref>; <xref ref-type="bibr" rid="B39">Thakur et al., 2020</xref>; <xref ref-type="bibr" rid="B1">Abdul et al., 2020</xref>; <xref ref-type="bibr" rid="B8">Jacob et al., 2020</xref>).</p>
</sec>
<sec id="s2-12">
<title>Skin safety evaluation</title>
<p>According to a prior report, a skin safety evaluation was conducted (<xref ref-type="bibr" rid="B7">Im et al., 2020</xref>). In summary, skin safety testing involved determining skin irritation through a medical exam and interview after 1, 2, and 4&#xa0;weeks of product use (<xref ref-type="bibr" rid="B7">Im et al., 2020</xref>).</p>
</sec>
<sec id="s2-13">
<title>Physical stability and microbial assessment</title>
<p>The prepared Hyaluronic acid Tretinoin SLN (H-T-SLN) was kept in accelerated stability studies (40&#xb0;C &#xb1; 2&#xb0;C/75% &#xb1; 5% RH) for 6&#xa0;months (<xref ref-type="table" rid="T2">Table 2</xref>). A physicochemical analysis including description, odor, pH, particle size, PDI, viscosity and microbial assessments was performed in the initial, 3rd and 6th months.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Stability results until 6&#xa0;months with 40<inline-formula id="inf4">
<mml:math id="m7">
<mml:mrow>
<mml:mo>&#x2103;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>
</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">Test</th>
<th colspan="3" align="center">Results</th>
<th rowspan="2" align="left">Limits</th>
</tr>
<tr>
<th align="center">Initial</th>
<th align="center">3rd Month</th>
<th align="center">6th Month</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Order</td>
<td align="center">Complies</td>
<td align="center">Complies</td>
<td align="center">Complies</td>
<td align="left">Characteristic order</td>
</tr>
<tr>
<td align="left">Description</td>
<td align="center">Complies</td>
<td align="center">Complies</td>
<td align="center">Complies</td>
<td align="left">Clear Yellowish</td>
</tr>
<tr>
<td align="left">Particle size</td>
<td align="center">
<bold>750 &#xb1; 31.29</bold>
</td>
<td align="center">Nil</td>
<td align="center">
<bold>710 &#xb1; 41.12</bold>
</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">pH</td>
<td align="center">
<bold>6.5</bold>
</td>
<td align="center">
<bold>6.3</bold>
</td>
<td align="center">
<bold>6.5</bold>
</td>
<td align="left">6&#x2013;6.5</td>
</tr>
<tr>
<td align="left">PDI</td>
<td align="center">
<bold>0.24 &#xb1; 0.12</bold>
</td>
<td align="center"/>
<td align="center">
<bold>0.27 &#xb1; 0.22</bold>
</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">Viscosity</td>
<td align="center">
<bold>80cpi</bold>
</td>
<td align="center">
<bold>83cpi</bold>
</td>
<td align="center">
<bold>79cpi</bold>
</td>
<td align="left">75&#x2013;85cpi</td>
</tr>
<tr>
<td align="left">Total Aerobic Microbial Count (TAMC)</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="left">200&#xa0;cfu/mL</td>
</tr>
<tr>
<td align="left">Total Combined Yeasts &#x26; Molds Count (TYMC)</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="center">&#x3c;10&#xa0;cfu/mL</td>
<td align="left">20&#xa0;cfu/mL</td>
</tr>
<tr style="background-color:#BFBFBF">
<td colspan="5" align="center">Tests for Absence of specified Microorganisms</td>
</tr>
<tr>
<td align="left">
<italic>Staphylococcus aureus</italic>
</td>
<td align="center">Absent/mL</td>
<td align="center">Absent/mL</td>
<td align="center">Absent/mL</td>
<td align="left">Should be absent/mL</td>
</tr>
<tr>
<td align="left">
<italic>Pseudomonas aeruginosa</italic>
</td>
<td align="center">Absent/mL</td>
<td align="center">Absent/mL</td>
<td align="center">Absent/mL</td>
<td align="left">Should be absent/mL</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>a</sup>
</label>
<p>Nil means no limits were determined after 3<sup>rd</sup> month.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2-14">
<title>Study design</title>
<p>Hyaluronic acid tretinoin SLN (H-T-SLN) serum antiaging efficacy on face skin was examined in a 4-week, single-group clinical experiment (Female and Male) (13) Between September 2022 and October 2022, the research was conducted at the RLCP. The Rashid Latif College of Pharmacy and Medical College&#x2019;s institutional review board authorized the protocol in accordance with the rules established by the faculty of pharmacy at the college. Approval: IRB No (RLCP/EP/30/2022). Additionally, the study was conducted in compliance with the ethical standards of the Declaration of Helsinki and Good Clinical Practice (GCP). Before collecting their signed informed consent, all volunteers were taken of the study&#x2019;s approach. The participants were told to apply one fingertip unit of the H-T-SLN Serum on their face every day for 4&#xa0;weeks. Consent was taken from all participants and informed them about all experiments.</p>
</sec>
<sec id="s2-15">
<title>Inclusion and exclusion criteria</title>
<p>The following requirements were established as inclusion standards:<list list-type="simple">
<list-item>
<p>1. Good physical and health condition.</p>
</list-item>
<list-item>
<p>2. Age 40&#x2013;60</p>
</list-item>
<list-item>
<p>3. Volunteer (Female and Male) who completed the written agreement form used anti-wrinkle H-T-SLN serum once daily for 4&#xa0;weeks and underwent regular follow-up.</p>
</list-item>
</list>
</p>
<p>The prerequisites for exclusion were as follows:<list list-type="simple">
<list-item>
<p>1. Using injectable fillers, anti-aging therapies, or systemic or topically applied wrinkle creams within the last 12&#xa0;months.</p>
</list-item>
<list-item>
<p>2. Previous 3-month history of isotretinoin use.</p>
</list-item>
<list-item>
<p>3. Over the past 6&#xa0;months, there have been interventions such as laser therapy or comprehensive chemical peeling.</p>
</list-item>
<list-item>
<p>4. The existence of severe or cystic acne on the face.</p>
</list-item>
<list-item>
<p>5. Hypersensitivity issues.</p>
</list-item>
<list-item>
<p>6. Women who are expecting or nursing.</p>
</list-item>
</list>
</p>
</sec>
<sec id="s2-16">
<title>Visual evaluation of wrinkles in the skin</title>
<p>The procedure for evaluating skin wrinkles visually was carried out as previously mentioned (<xref ref-type="bibr" rid="B6">Im et al., 2018</xref>). In brief, the evaluation of winkles around the eyes was performed under specific lighting conditions. The evaluation was conducted by two evaluators using specified standards. Wrinkles were analysed and recorded at the end of the study. The mean evaluations for each assessor were generated and statistically examined (<xref ref-type="table" rid="T3">Table 3</xref>). During all procedures and subsequent visits, all adverse events were either reported by the subjects or observed by the researchers and noted.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Visual evaluation of wrinkles in the skin.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Description</th>
<th align="left">Grade</th>
<th align="left">Subjects before (0&#xa0;week)</th>
<th align="left">Subject after 4&#xa0;weeks</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">There are no skin wrinkles</td>
<td align="center">1</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">Thin wrinkles on the skin visible</td>
<td align="center">2</td>
<td align="left">7</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">There are many thin wrinkles on the skin</td>
<td align="center">3</td>
<td align="left">2</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">Deep wrinkles on the skin are visible</td>
<td align="center">4</td>
<td align="left">1</td>
<td align="left">1</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-17">
<title>Evaluation of skin wrinkle parameters using Visioscan<sup>&#xae;</sup> camera images</title>
<p>The Visioscan<sup>&#xae;</sup> camera is the ideal instrument for accurately assessing deeper and larger macro wrinkles, such as crow&#x2019;s feet. The measurement was performed using an oblique light source and a skin facsimile. The length, depth, and area of the wrinkles are measured in millimetres using a high-resolution camera that is positioned vertically next to the replica to transform them into digital form. Using a camera and software, the surface evaluation of living skin was assessed. Four clinical characteristics were calculated (<xref ref-type="table" rid="T4">Table 4</xref>) to provide a quantitative and qualitative description of the skin surface as an index: skin smoothness (Se), skin roughness (Se), scaliness (Se), and wrinkles (Se).</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Volunteer skin smoothness (Se), skin roughness (Se), scaliness (Se) and wrinkles (Se).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="left">Volunteer 0&#xa0;days and 4&#xa0;weeks</th>
<th align="left">Roughness</th>
<th align="left">Scaliness</th>
<th align="left">Smoothness</th>
<th align="left">Wrinkles</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left">1</td>
<td align="left">Before</td>
<td align="left">1.23</td>
<td align="left">2.54</td>
<td align="left">334.3</td>
<td align="left">45.65</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.12</td>
<td align="left">2.74</td>
<td align="left">382.4</td>
<td align="left">39.89</td>
</tr>
<tr>
<td rowspan="2" align="left">2</td>
<td align="left">Before</td>
<td align="left">1.27</td>
<td align="left">2.51</td>
<td align="left">324.3</td>
<td align="left">55.25</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.19</td>
<td align="left">2.54</td>
<td align="left">392.4</td>
<td align="left">49.89</td>
</tr>
<tr>
<td rowspan="2" align="left">3</td>
<td align="left">Before</td>
<td align="left">1.33</td>
<td align="left">2.44</td>
<td align="left">328.3</td>
<td align="left">41.35</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.21</td>
<td align="left">2.84</td>
<td align="left">382.4</td>
<td align="left">37.29</td>
</tr>
<tr>
<td rowspan="2" align="left">4</td>
<td align="left">Before</td>
<td align="left">1.33</td>
<td align="left">2.44</td>
<td align="left">314.3</td>
<td align="left">43.25</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.10</td>
<td align="left">2.90</td>
<td align="left">361.4</td>
<td align="left">37.19</td>
</tr>
<tr>
<td rowspan="2" align="left">5</td>
<td align="left">Before</td>
<td align="left">1.43</td>
<td align="left">2.54</td>
<td align="left">368.3</td>
<td align="left">45.25</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.42</td>
<td align="left">2.88</td>
<td align="left">392.4</td>
<td align="left">43.99</td>
</tr>
<tr>
<td rowspan="2" align="left">6</td>
<td align="left">Before</td>
<td align="left">1.42</td>
<td align="left">2.94</td>
<td align="left">398.3</td>
<td align="left">41.05</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.32</td>
<td align="left">2.92</td>
<td align="left">392.4</td>
<td align="left">39.99</td>
</tr>
<tr>
<td rowspan="2" align="left">7</td>
<td align="left">Before</td>
<td align="left">1.91</td>
<td align="left">2.85</td>
<td align="left">351.9</td>
<td align="left">55.69</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.90</td>
<td align="left">2.94</td>
<td align="left">372.3</td>
<td align="left">49.19</td>
</tr>
<tr>
<td rowspan="2" align="left">8</td>
<td align="left">Before</td>
<td align="left">1.33</td>
<td align="left">2.74</td>
<td align="left">344.3</td>
<td align="left">55.15</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.32</td>
<td align="left">2.82</td>
<td align="left">392.4</td>
<td align="left">49.29</td>
</tr>
<tr>
<td rowspan="2" align="left">9</td>
<td align="left">Before</td>
<td align="left">1.53</td>
<td align="left">2.74</td>
<td align="left">304.3</td>
<td align="left">45.75</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.42</td>
<td align="left">2.94</td>
<td align="left">362.4</td>
<td align="left">42.80</td>
</tr>
<tr>
<td rowspan="2" align="left">10</td>
<td align="left">Before</td>
<td align="left">1.53</td>
<td align="left">2.84</td>
<td align="left">333.3</td>
<td align="left">66.65</td>
</tr>
<tr>
<td align="left">After</td>
<td align="left">1.50</td>
<td align="left">2.94</td>
<td align="left">382.4</td>
<td align="left">61.12</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-18">
<title>Analytical statistics</title>
<p>One-way ANOVA and Tukey&#x2019;s test were used in the statistical analysis, which was performed using the GraphPad Prism v.5 program. The mean and standard deviation were used to depict the data (SD). Statistical significance was defined as a <italic>p</italic>-value of 0.05.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and discussion</title>
<sec id="s3-1">
<title>Fabrication of SLN by the solvent emulsification diffusion method</title>
<p>Due to its relatively high cutaneous tolerability compared to other partially miscible solvents, ethanol was chosen for the current experiment as a miscible solvent for the synthesis of SLN and we have use the method as mentioned by <xref ref-type="bibr" rid="B40">Trotta et al. (2003)</xref>. Additionally, at a temperature of 50&#xb0;C, ethanol has a significant solubilizing capacity for tretinoin and cetostearyl alcohol. In this study, hyaluronic acid polymer was also used, and adding it to the SLN synthesis process made the particles more polydisperse (with a greater hydrodynamic radius). Hyaluronic acid has great potential for skin treatments. Hyaluronic acid helps skin stretch and reduces skin wrinkles and lines. The entrapment efficiency of SLN was 90.07 <inline-formula id="inf5">
<mml:math id="m8">
<mml:mrow>
<mml:mo>&#xb1;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> 4.79%. %. The strong affinity of the lipophilic medication for the lipidic substance, as stated by <xref ref-type="bibr" rid="B45">Souto et al. (2004)</xref>, is likely the cause of this outcome. The production yields that were attained were typically high, ranging from 75%&#x2212;80%. After the preparation of hyaluronic acid tretinoin, SLN (H-T-SLN) was converted into serum by using glycerin. <xref ref-type="fig" rid="F2">Figure 2</xref> shows the spectra of tretinoin.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Maximum absorbance of tretinoin in UV absorbance (standard and samples (H-T-SLN) were compared at 295&#xa0;nm).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Particle size, polydispersity index (PDI) and zeta potentials</title>
<p>Hyaluronic acid tretinoin SLN (H-T-SLN), size distribution and charge were determined by using DLS. Deionized water from a Milli-Q system was used for the measurements (1&#xa0;mL/10&#xa0;mL). <xref ref-type="fig" rid="F3">Figure 3</xref> depicts a size distribution diagram of hyaluronic acid tretinoin SLN (H-T-SLN). The hyaluronic acid tretinoin SLN (H-T-SLN) has a hydrodynamic diameter of 750 &#xb1; 23.89<bold>&#xa0;</bold>nm and a PDI of 0.276 <inline-formula id="inf6">
<mml:math id="m9">
<mml:mrow>
<mml:mo>&#xb1;</mml:mo>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mn>0.03</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>, according to the DLS data. At a temperature of 25 <inline-formula id="inf7">
<mml:math id="m10">
<mml:mrow>
<mml:mo>&#xb1;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> 0.5&#xb0;C, the zeta potential of the hyaluronic acid tretinoin SLN (H-T-SLN) was measured using a Malvern Zetasizer ZS200. For each sample, at least three measurements were taken. Hyaluronic acid tretinoin SLN (H-T-SLN) zeta potentials were typically approximately &#x2212;16&#xa0;mV, which is enough to completely stabilize the system. Same PDI was observed in the SLN formulation of <xref ref-type="bibr" rid="B36">Schubert and M&#xfc;ller-Goymann (2005)</xref>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Particle size distribution measurements of (H-T-SLN) using a Malvern Instruments Zetasizer Nano ZS. Deionized water from a Milli-Q system was used for the measurements.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>FT-IR analysis</title>
<p>FTIR spectroscopy was used in the region of 600&#x2013;4,000&#xa0;cm<sup>&#x2212;1</sup>. The synthesized hyaluronic acid tretinoin SLN (H-T-SLN) was examined for the identification and characterization of functional groups present. O-H stretching vibrations are shown by the peak at 3,438&#xa0;cm<sup>&#x2212;1</sup>, C &#x3d; O stretching is represented by the band at 2,901.10&#xa0;cm<sup>&#x2212;1</sup>, and the trans vinyl (CH &#x3d; CH) groups of the tretinoin molecule are shown by the peak at 960&#xa0;cm<sup>&#x2212;1</sup> (<xref ref-type="bibr" rid="B28">Phadtare et al., 2016</xref>).</p>
<p>Hyaluronic acid revealed several distinctive bands. Strong absorption bands were observed at 3,435.24&#xa0;cm<sup>&#x2212;1</sup>, which correspond to the stretching vibrations of OH. The bands at 1,632.53&#xa0;cm<sup>&#x2212;1</sup>, 1,553.51&#xa0;cm<sup>&#x2212;1</sup> and 1,320.33&#xa0;cm<sup>&#x2212;1</sup> can be attributed to amide, while the absorption bands at 1,155.32&#xa0;cm<sup>&#x2212;1</sup>, 1,064.12&#xa0;cm<sup>1</sup>, 1040.67&#xa0;cm<sup>&#x2212;1</sup> and 944.61&#xa0;cm<sup>&#x2212;1</sup> are characteristic of carbohydrates.</p>
<p>For hyaluronic acid tretinoin SLN (H-T-SLN), distinctive peaks are shown in <xref ref-type="fig" rid="F4">Figure 4</xref>, in which 2,919&#xa0;cm<sup>&#x2212;1</sup> (C &#x3d; O stretching of tretinoin group) was noticed, which was slightly changed from 2,901.10. The peak intensity of O-H also changed slightly, going from 3,435.24 to 3,432.14&#xa0;cm<sup>&#x2212;1</sup>. Other peaks were also found after slight shifts of 1,064.12&#xa0;cm<sup>&#x2212;1</sup> to 1,084.82 and 960&#xa0;cm<sup>&#x2212;1</sup> to 956&#xa0;cm<sup>&#x2212;1</sup>, which indicate that the carbohydrate group from hyaluronic acid and vinyl group from tretinoin, were present under the same conditions. It can be concluded that there was minimal interaction between tretinoin and hyaluronic acid polymer, as evidenced by the change in peak intensity, which was a sign of chemical and physical changes occurring during the SLN formation process. This interaction resulted in a high entrapment efficiency of tretinoin into the polymer.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>FTIR analysis of tretinoin, hyaluronic and hyaluronic acid tretinoin SLN (H-T-SLN).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Thermal analysis</title>
<p>Thermal analysis (Q-2000, TA, United States) was used to evaluate tretinoin, hyaluronic acid and hyaluronic acid tretinoin SLN (H-T-SLN). The temperature range was 0&#xb0;C&#x2013;300&#xb0;C adjusted at a heating rate of 20&#xb0;C/min. <xref ref-type="fig" rid="F5">Figure 5</xref> shows the DSC thermograms of tretinoin, hyaluronic acid and hyaluronic acid tretinoin SLN (H-T-SLN). The melting point of tretinoin, 194&#xb0;C, was shown by a significant rise in the crystallinity of the compound. Additionally, an exothermic peak is observed at approximately 150&#xb0;C, indicating an exothermic reaction caused by crystallization. Hyaluronic acid also showed an endothermic peak at approximately 55&#x2103;, an exothermic peak at approximately 150<inline-formula id="inf8">
<mml:math id="m11">
<mml:mrow>
<mml:mo>&#x2103;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> and a final exothermic peak at 210&#x2103; and 245&#xb0;C which is melting point of Hyaluronic acid. A totally amorphous version of the polymer known as hyaluronic acid exists at a glass transition temperature (Tg) of approximately 210&#x2103;. Hyaluronic acid tretinoin SLN (H-T-SLN) displayed a broad endothermic peak at 25.4&#xb0;C in contrast to tretinoin, which was due to dehydration and elimination of volatile components. A second endothermic peak was observed at 155&#x2103;, which was due to tretinoin amorphous dispersion in the lipid matrix, and this indication showed that tretinoin crystals convert into an amorphous phase that becomes more soluble.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Thermal analysis (DSC) of pure tretinoin, hyaluronic acid polymer and (H-T-SLN).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g005.tif"/>
</fig>
<p>The same tool and process were used to calculate weight loss. The weight loss of tretinoin began between 50&#xb0;C and 120&#x2103;, and a total weight loss of 60% was observed in TGA (<xref ref-type="fig" rid="F6">Figure 6</xref>). At a glass transition temperature (Tg) of approximately 175&#xb0;C, the polymer known as hyaluronic acid exists in a completely amorphous state. At 175&#xb0;C and 250&#xb0;C, for hyaluronic acid, TGA also showed a weight loss of 70%. The weight loss of hyaluronic acid tretinoin SLN (H-T-SLN) was significantly changed due to drug and polymer interactions within lipid molecules. TGA showed a total weight loss of 40%, which started from 75&#x2103; to 178&#x2103;.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Thermal analysis (TGA) of pure tretinoin, hyaluronic acid polymer and (H-T-SLN).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Morphology analysis</title>
<p>Scanning electron microscopy was used to directly observe the morphological appearance of the SLN. H-T-SLN was shown to be spherical in shape after the particles were scanned under an electron microscope. Scanning electron microscopy (SEM) micrographs of pure treatment and an optimized SLN formulation clearly demonstrated significant differences. The ordered shape of H-T-SLN may be the result of phase evaporation during particle hardening. <xref ref-type="fig" rid="F7">Figure 7A</xref> shows a scanning electron microscopic view (SEM) of H-T-SLN, which showed well-dispersed particles. The results showed that successful SLN with ordered shapes were prepared from API crystalline particles, as shown in <xref ref-type="fig" rid="F7">Figure 7B</xref>, which depicts large crystal particles.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Images of pure tretinoin crystal form <bold>(B)</bold> and H-T-SLN particles <bold>(A)</bold>.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g007.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>X-ray diffraction (XRD)</title>
<p>The tretinoin diffraction pattern revealed five main distinct peaks at 16.519 2&#x3b8;, 22.603&#xb0; 2&#x3b8;, 24.004, and 39.482 2&#x3b8;, indicating its crystalline nature, as shown in <xref ref-type="fig" rid="F8">Figure 8</xref>. In the diffractogram of the H-T-SLN, these peaks could not be seen except two with low intensity, indicating that the tretinoin was dissolved inside the lipid matrix of the SLN and stabilized in an amorphous state. Because of its limited solubility in water, tretinoin would crystallize if it were present outside of the lipid matrix, which should have had an impact on the diffraction patterns of drug-loaded SLN. This shows that the medication was successfully absorbed into the SLN lipid matrix. Additionally, XRD spectra between angles 15.219 2&#x3b8; and 28.503&#xb0; 2&#x3b8; showed lower intensity in H-T-SLN than in hyaluronic acid, which indicates lower crystallinity in comparison to neat tretinoin and hyaluronic acid. This observation can be explained by the fact that tretinoin was trapped in the lipid core of SLN.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>XRD patterns of pure tretinoin, hyaluronic acid and H-T-SLN.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g008.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>
<italic>In vitro</italic> release study</title>
<p>Tretinoin pure medication and H-T-SLN were checked for dissolution in two buffers for up to 60&#xa0;min. The release profile from both types is shown in <xref ref-type="fig" rid="F9">Figure 9</xref>. The H-T-SLN particle release profile displayed an immediate release pattern that was biphasic in nature (<xref ref-type="fig" rid="F7">Figure 7</xref>). The mean particle size of the H-T-SLN samples employed in this study was 750&#xa0;nm (PDI-0.276), which is helpful for increasing the dissolution of H-T-SLN particles in both media, and its rapid dissolution results in immediate absorbance. The aqueous solubility of tretinoin is very low, 2% (w/v). It displayed a nearly identical pattern of low solubility in both media. The percent cumulative drug release versus time was plotted to demonstrate the drug release pattern (<xref ref-type="fig" rid="F9">Figure 9</xref>). The results demonstrated that drug release from the H-T-SLN particles was very fast. The drug release after 30&#xa0;min was above 85% &#xb1; 3.79% in both media. Comparative results shown by <xref ref-type="bibr" rid="B21">Mishra et al. (2018)</xref> in his research which was 99.78 &#xb1; 0.78 within 120&#xa0;min in this they prepared ethosomes of tretinoin for acne treatment. We have also checked H-T-SLN on 5.5 pH because this is skin pH and we have observed significant release pattern on this pH 83.12% in 30&#xa0;min and 100.00% in 60&#xa0;min.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>
<italic>In vitro</italic> drug release profile of pure drug and formulation studied in acidic buffer pH 1.2, phosphate buffer pH 5.5 and 7.4 according to dialysis bag membrane method (n &#x3d; 3).</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g009.tif"/>
</fig>
<p>Burst release was observed within 10&#xa0;min in both buffers, followed by a continuous drug release pattern and 100% and 97% dissolution within 60&#xa0;min in both buffers. Comparative results we have found in research which was conducted by <xref ref-type="bibr" rid="B23">Montassier et al. (1998)</xref>.</p>
</sec>
<sec id="s3-8">
<title>Haemolysis investigations</title>
<p>Through hemolytic studies, the compatibility of the H-T-SLN particles with the blood of rats was examined. Hemolytic analyses revealed that H-T-SLN particles did not cause hemolysis after administration at concentrations of 100, 150, and 200&#xa0;mg&#xa0;mL&#x2212;<sup>1</sup>; however, negligible hemolysis was noted even at high concentrations (5.353, 7.840, and 10.580%), i.e., 200&#xa0;mg&#xa0;mL&#x2212;<sup>1</sup>, and blood cells demonstrated good tolerance to the complex (<italic>p</italic> &#x3c; 0.0001). Relevant study was done by <xref ref-type="bibr" rid="B3">Ali et al. (2018)</xref> in which he shown 15.34% &#xb1; 0.89% and 19.67% &#xb1; 1.29% hemolysis for 500 and 1,000&#xa0;&#x3bc;g&#xa0;mL<sup>&#x2013;1</sup> concentrations of SLN. The current study&#x2019;s findings showed (<xref ref-type="fig" rid="F10">Figure 10</xref>) that cell viability relied on concentration and that cells were still alive after being incubated with H-T-SLN, confirming the compatibility of the substance with human blood.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>The compatibility of H-T-SLN particles with blood.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g010.tif"/>
</fig>
</sec>
<sec id="s3-9">
<title>Physical stability and microbial assessment</title>
<p>After converting H-T-SLN into a serum formulation, we determined its stability and total aerobic microbial count (TAMC). The H-T-SLN serum formulation was developed for skin applications. Stability tests were performed for H-T-SLN using a stability chamber in which H-T-SLN was held at 40&#xb0;C for 6&#xa0;months. On the initial day, after 3&#xa0;months and after 6&#xa0;months, H-T-SLN, order, description, pH, particle size, PDI and viscosity were each examined. The pH of the H-T-SLN serum formulation was found to be 6.3 to 6.5, which is appropriate for skin products. The formulation&#x2019;s viscosity at 25&#xb0;C was 79 to 80&#xa0;cpi, making it appropriate for skin application as well. For H-T-SLN, serum homogeneity and clarity were deemed satisfactory. Particle size and PDI was also determined after 6th month to ensure particles stability and found satisfactory. It was 750 &#xb1; 31.29, 0.24 &#xb1; 0.12 in initial and after 6th month it was 710 &#xb1; 41.12, 0.27 &#xb1; 0.22.</p>
<p>H-T-SLN serum must comply with all USP 43 requirements before being made into a scaled-up formulation for patients (<xref ref-type="bibr" rid="B2">Adriaensen et al., 2017</xref>). The microbiological parameters of H-T-SLN serum were also checked. TAMC, TYMC, <italic>Staphylococcus</italic>, and <italic>Pseudomonas</italic> were examined in H-T-SLN for up to 6&#xa0;months. To prepare the plates, Sabouraud Dextrose Agar and Nutrient Agar were used, and the method was described in the publication by <xref ref-type="bibr" rid="B4">Ballal et al. (2009)</xref>. Plates were incubated in Memmert incubators for 72&#xa0;h TAMC and 7&#xa0;days for TYMC at different temperatures (32&#x2103; &#xb1; 2 and 22&#x2103; &#xb1; 2). The results shown in <xref ref-type="table" rid="T2">Table 2</xref> are quite satisfactory until the 6th month.</p>
</sec>
<sec id="s3-10">
<title>
<italic>In vitro</italic> permeability</title>
<p>The primary goal of the current investigation was to evaluate the <italic>in vitro</italic> permeability of H-T-SLN over a silica membrane (pH 6.8). Clean, dry receptor cells filled with deaerated buffer were used in this investigation. The mixture was stirred continuously with a magnetic stirrer for 30&#xa0;min at 37&#xb0;C. To stop direct evaporation, para-film was used to plug the apertures. To stir the receptor compartment, a speed of 200&#xa0;rpm was maintained. <xref ref-type="bibr" rid="B15">Kr&#xfc;ger (2010)</xref> mentioned in his experiments that SLN preparation are more absorbable through skin (<xref ref-type="bibr" rid="B15">Kr&#xfc;ger, 2010</xref>). Drug diffusion was measured using a prehydrated silica membrane. A 0.5&#xa0;mL sample was obtained using a glass syringe from the receptor cell for UV analysis at 295&#xa0;nm wavelength. <xref ref-type="fig" rid="F11">Figure 11</xref> depicts the results, which revealed that at pH 6.8, H-T-SLN diffused twice as much within a short time as pure medication. This enhancement has been made possible by the lower particle sizes obtained using the precipitation process of manufacturing SLN. The apparent permeability constant Papp was calculated according to Fick&#x2019;s first law of diffusion (<xref ref-type="bibr" rid="B31">Reichling et al., 2006</xref>). The values for flux and apparent permeation coefficient of H-T-SLN were calculated according to Fick&#x2019;s first law of diffusion. Flux of H-T-SLN through silica membrane (<inline-formula id="inf9">
<mml:math id="m12">
<mml:mrow>
<mml:mi>&#x3bc;</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>L/cm<sup>2</sup> h) mean &#xb1; SE (0.021 &#xb1; 0.002). Papp of H-T-SLN according to Fick&#x2019;s first law was 2.64 &#xb1; 0.04 (cm/s). (Data of suspension is not included in manuscript).</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>Tretinoin release in the form of a suspension through a silicon membrane compared with H-T-SLN release.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g011.tif"/>
</fig>
</sec>
<sec id="s3-11">
<title>Skin safety evaluation</title>
<p>For skin safety evaluation, skin irritation and skin dermatitis were viewed after applying H-T-SLN serum on the subject&#x2019;s face after consent. Before applying the H-T-SLN serum on the subject&#x2019;s face, it was cleaned with soap, and the skin was dried with tissue. After this, 1&#xa0;g of H-T-SLN serum was gently applied to the face skin with fingers. After 24&#xa0;h, the skin was observed visually and found to be healthy. No irritation or dermatitis marks appeared on the skin, which indicated that the H-T-SLN serum is safe for skin use. Follow chart shown in <xref ref-type="fig" rid="F12">Figure 12</xref>.</p>
<fig id="F12" position="float">
<label>FIGURE 12</label>
<caption>
<p>Flow chart of the subject allocation process.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g012.tif"/>
</fig>
</sec>
<sec id="s3-12">
<title>Visual assessment of skin wrinkles</title>
<p>To determine the ameliorating effect of H-T-SLN on wrinkle formation, wrinkles around the eyes of the subjects were evaluated independently under specific lighting conditions. Skin damage was determined by visual assessment, and no irritation, damage or side effects were found in any of the subjects. A 4&#xa0;week study was conducted, and 60% of the subjects found a significant decrease in wrinkles with daily use of H-T-SLN.</p>
</sec>
<sec id="s3-13">
<title>Evaluation of skin wrinkle parameters using Visioscan<sup>&#xae;</sup> camera images</title>
<p>The objective of this study was to evaluate through objective and subjective analysis the long-term effects of H-T-SLN serum containing tretinoin and hyaluronic acid. H-T-SLN was applied to the face skin of 10 volunteers (skin pictures of three voluntaries are shown in <xref ref-type="fig" rid="F13">Figure 13</xref>). Skin smoothness (Se), skin roughness (Se), scaliness (Se) and wrinkles (Se) were determined after 4&#xa0;weeks of daily application. One of the volunteer skin surfaces is shown in <xref ref-type="fig" rid="F13">Figure 13</xref>. The results showed significant changes in parameters such as skin tightness, which may be produced by surface deposition of certain film-forming polymers and tretinoin. <xref ref-type="table" rid="T3">Table 3</xref> shows all volunteers&#x2019; skin smoothness (Se), skin roughness (Se), scaliness (Se) and wrinkles (Se). The moisturizing effects (glycerin) could, in addition, reduce the irritant effects of anti-aging treatments such as those with tretinoin.</p>
<fig id="F13" position="float">
<label>FIGURE 13</label>
<caption>
<p>Surface of the skin of a three volunteers who applied (H-T-SLN) serum before <bold>(A&#x2013;C)</bold> 4&#xa0;weeks of application. The skin surface was evaluated by Visioscan<sup>&#xae;</sup> VC98 software after 4&#xa0;weeks <bold>(A1&#x2013;C1)</bold>.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g013.tif"/>
</fig>
<p>The clinical portion of our investigation involved ten participants with mild to advanced wrinkles (<xref ref-type="table" rid="T3">Table 3</xref>) who were both sexes and between the ages of 40 and 60 (mean age, 40 <inline-formula id="inf10">
<mml:math id="m13">
<mml:mrow>
<mml:mo>&#xb1;</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> 8.76&#xa0;years). There were no significant side effects seen, and there were no reports of skin erythema, burning, itching, or peeling throughout the course of treatment. Ninety percent of individuals improved by at least one grade after 4&#xa0;weeks of treatment, according to the subjective efficacy evaluation (<xref ref-type="table" rid="T4">Table 4</xref>). Additionally, after the procedure, the volunteer reported feeling &#x201c;moderately happy.&#x201d; In both follow-up visits, there was a noticeable reduction in the volume and wrinkle area of the nasolabial folds according to objective measurements. In the fourth week, the wrinkle area decreased from 41&#x2013;66 (baseline) to 37&#x2013;6. Finally, there was no discernible change in the moisture of the skin.</p>
</sec>
<sec id="s3-14">
<title>Critical quality attributes (CQAs)</title>
<p>The FDA issued guidelines for the industry in 2018 regarding the development of SLN particles medicinal products, citing a number of crucial quality attributes (CQAs) that require attention. These CQAs are shown in <xref ref-type="fig" rid="F14">Figure 14</xref> and include: physical characteristics, particle size, drug entrapment, drug diffusion and drug release and stability structure. We cover here the methodologies and technologies that have been used to describe SLN pharmaceutical formulations, with an emphasis on CQAs, in an effort to better characterize and successfully develop these formulations.</p>
<fig id="F14" position="float">
<label>FIGURE 14</label>
<caption>
<p>Critical Quality Attributes (CQAs) Fish bone diagram.</p>
</caption>
<graphic xlink:href="fphar-15-1401594-g014.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>SLN nanotransporters are efficient carriers for drug delivery to the skin. Due to the superior ratio of particle surface to volume, small sized SLN nanotransportare most promising for skin delivery. This mechanism even surmounts the effect of mixing of epidermal lipids and the matrix lipids of SLN, which can facilitate penetration especially of drugs. Hyaluronic acid based SLN with tretinoin loading were developed for topical delivery. H-T-SLN was shown to have been converted to an amorphous state by DSC and XRD tests. Hemolysis assay shown that H-T-SLN is compatible rat blood and there is no toxic effect of H-T-SLN. The improved H-T-SLN formulation remained stable for over 6&#xa0;months at 40&#x2103;. Further we have converted it into serum form for easy applications. In conclusion, this investigation showed H-T-SLN serum resulted in wrinkles reduction in the human. In addition, the daily use of these substances is very important to protect the barrier function of the skin, The immediate effects observed in the short term study were confirmed in the long term evaluation.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Rashid Latif College of Pharmacy and Medical College&#x2019;s institutional review board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. The animal studies were approved by The Rashid Latif College of Pharmacy and Medical College&#x2019;s institutional review board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>YM: Writing&#x2013;original draft, Writing&#x2013;review and editing. HS: Writing&#x2013;review and editing, Writing&#x2013;original draft. SR: Conceptualization, Writing&#x2013;original draft, Writing&#x2013;review and editing. UJ: Software, Writing&#x2013;original draft, Writing&#x2013;review and editing. NA: Methodology, Writing&#x2013;original draft, Writing&#x2013;review and editing. MN: Data curation, Writing&#x2013;original draft. MDH: Writing&#x2013;original draft, Project administration. MK: Formal Analysis, Writing&#x2013;original draft, Writing&#x2013;review and editing. </p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors would like to extend their sincere appreciation to the Researchers Supporting Project Number (RSPD2024R994), King Saud University, Riyadh, Saudi Arabia.</p>
</sec>
<ack>
<p>The authors would like to extend their sincere appreciation to the Researchers Supporting Project Number (RSPD2024R994), King Saud University, Riyadh, Saudi Arabia.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdul</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Bala</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Chintaginjala</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Manchikanti</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Kamsali</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Dasari</surname>
<given-names>R. R. D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Equator assessment of nanoparticles using the design-expert software</article-title>. <source>Int. J. Pharm. Sci. Nanotechnol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>4766</fpage>&#x2013;<lpage>4772</lpage>. <pub-id pub-id-type="doi">10.37285/ijpsn.2020.13.1.5</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adriaensen</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Fokkens</surname>
<given-names>W. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Safety and efficacy of a bioabsorbable fluticasone propionate&#x2013;eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial</article-title>. <source>Int. forum allergy and rhinology</source> <volume>7</volume>, <fpage>813</fpage>&#x2013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1002/alr.21963</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Yousuf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Javed</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Hemolytic and cellular toxicology of a sulfanilamide-based nonionic surfactant: a niosomal carrier for hydrophobic drugs</article-title>. <source>Toxicol. Res.</source> <volume>7</volume> (<issue>5</issue>), <fpage>771</fpage>&#x2013;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1039/c8tx00108a</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballal</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kundabala</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Acharya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ballal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Susceptibility of Candida albicans and <italic>Enterococcus faecalis</italic> to Chitosan, Chlorhexidine gluconate and their combination <italic>in vitro</italic>
</article-title>. <source>Aust. Endod. J.</source> <volume>35</volume> (<issue>1</issue>), <fpage>29</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-4477.2008.00126.x</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barkat</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Usman Minhas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nasir</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Development and characterization of pH&#x2010;responsive polyethylene glycol&#x2010;co&#x2010;poly (methacrylic acid) polymeric network system for colon target delivery of oxaliplatin: its acute oral toxicity study</article-title>. <source>Adv. Polym. Technol.</source> <volume>37</volume> (<issue>6</issue>), <fpage>1806</fpage>&#x2013;<lpage>1822</lpage>. <pub-id pub-id-type="doi">10.1002/adv.21840</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Im</surname>
<given-names>A.-R.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Chae</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Wrinkle reduction using a topical herbal cream in subjects with greater yin (Tae-eumin) type: a randomized double-blind placebo-controlled study</article-title>. <source>Eur. J. Integr. Med.</source> <volume>20</volume>, <fpage>173</fpage>&#x2013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.eujim.2018.05.004</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Im</surname>
<given-names>A.-R.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>Y. K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Wrinkle reduction using a topical herbal cream in subjects classified by Sasang constitutional medicine as Soyang type: a randomized double-blind placebo-controlled study</article-title>. <source>Eur. J. Integr. Med.</source> <volume>35</volume>, <fpage>101070</fpage>. <pub-id pub-id-type="doi">10.1016/j.eujim.2020.101070</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Emerging role of nanosuspensions in drug delivery systems</article-title>. <source>Biomaterials Res.</source> <volume>24</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1186/s40824-020-0184-8</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jose</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Netto</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of solid lipid nanoparticles as photoprotective agents in cosmetics</article-title>. <source>J. Cosmet. Dermatology</source> <volume>18</volume> (<issue>1</issue>), <fpage>315</fpage>&#x2013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1111/jocd.12504</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juncan</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Mois&#x103;</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morgovan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rus</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Vonica-&#x21a;incu</surname>
<given-names>A. L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Advantages of hyaluronic acid and its combination with other bioactive ingredients in cosmeceuticals</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>15</issue>), <fpage>4429</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26154429</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karami</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Abdouss</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Cutting-edge tumor nanotherapy: advancements in 5-fluorouracil Drug-loaded chitosan nanoparticles</article-title>. <source>Inorg. Chem. Commun.</source> <volume>164</volume>, <fpage>112430</fpage>. <pub-id pub-id-type="doi">10.1016/j.inoche.2024.112430</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cardona</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benitez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rendon</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature</article-title>. <source>Cutis</source> <volume>81</volume> (<issue>2</issue>), <fpage>179</fpage>&#x2013;<lpage>183</lpage>.</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalid</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Minhas</surname>
<given-names>M. U.</given-names>
</name>
<name>
<surname>Barkat</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Preparation and characterization of alginate-PVA-based semi-IPN: controlled release pH-responsive composites</article-title>. <source>Polym. Bull.</source> <volume>75</volume> (<issue>3</issue>), <fpage>1075</fpage>&#x2013;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1007/s00289-017-2079-y</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. G.</given-names>
</name>
<name>
<surname>Kweon</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Investigations on skin permeation of hyaluronic acid based nanoemulsion as transdermal carrier</article-title>. <source>Carbohydr. Polym.</source> <volume>86</volume> (<issue>2</issue>), <fpage>837</fpage>&#x2013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2011.05.027</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Kr&#xfc;ger</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2010</year>). <source>Formulation, in vitro release and transdermal diffusion of selected retinoids</source>. <publisher-name>North-West University</publisher-name>.</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehmood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>I. U.</given-names>
</name>
<name>
<surname>Shahzad</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Asghar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Irfan</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Facile synthesis of mesoporous silica nanoparticles using modified solgel method: optimization and <italic>in vitro</italic> cytotoxicity studies</article-title>. <source>Pak. J. Pharm. Sci.</source> <volume>32</volume> (<issue>4</issue>), <fpage>1805</fpage>&#x2013;<lpage>1812</lpage>.</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehmood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>I. U.</given-names>
</name>
<name>
<surname>Shahzad</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>R. U.</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>H. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>
<italic>In-vitro</italic> and <italic>in-vivo</italic> evaluation of velpatasvir-loaded mesoporous silica scaffolds. A prospective carrier for drug bioavailability enhancement</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>4</issue>), <fpage>307</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12040307</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehmood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Arshad</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rasul</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jamshaid</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jamshaid</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Amikacin-loaded chitosan hydrogel film cross-linked with folic acid for wound healing application</article-title>. <source>Gels</source> <volume>9</volume> (<issue>7</issue>), <fpage>551</fpage>. <pub-id pub-id-type="doi">10.3390/gels9070551</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehmood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Barkat</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Arshad</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rasul</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M. N.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>Novel hydrolytic degradable crosslinked interpenetrating polymeric networks (IPNs): an efficient hybrid system to manage the controlled release and degradation of misoprostol</article-title>. <source>Gels</source> <volume>9</volume> (<issue>9</issue>), <fpage>697</fpage>. <pub-id pub-id-type="doi">10.3390/gels9090697</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehmood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ul Huq</surname>
<given-names>U. I.</given-names>
</name>
<name>
<surname>Rafeeq</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>H. M. B.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M. N.</given-names>
</name>
<etal/>
</person-group> (<year>2023c</year>). <article-title>Microsponge-based gel loaded with immunosuppressant as a simple and valuable strategy for psoriasis therapy: determination of pro-inflammatory response through cytokine IL-2 mRNA expression</article-title>. <source>Gels</source> <volume>9</volume> (<issue>11</issue>), <fpage>871</fpage>. <pub-id pub-id-type="doi">10.3390/gels9110871</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shende</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Formulation and evaluation of gel containing ethosomes entrapped with tretinoin</article-title>. <source>J. Drug Deliv. Ther.</source> <volume>8</volume> (<issue>5-s</issue>), <fpage>315</fpage>&#x2013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.22270/jddt.v8i5-s.1982</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monheit</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Hyaluronic acid fillers</article-title>. <source>Dermatol. Ther.</source> <volume>19</volume> (<issue>3</issue>), <fpage>141</fpage>&#x2013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1111/j.1529-8019.2006.00068.x</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montassier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Duch&#xea;ne</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Poelman</surname>
<given-names>M.-C.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>
<italic>In vitro</italic> release study of tretinoin from tretinoin/cyclodextrin derivative complexes</article-title>. <source>J. inclusion Phenom. Mol. Recognit. Chem.</source> <volume>31</volume>, <fpage>213</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1023/a:1007940722402</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montenegro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Offerta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sarpietro</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Micicch&#xe8;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maccioni</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>From nanoemulsions to nanostructured lipid carriers: a relevant development in dermal delivery of drugs and cosmetics</article-title>. <source>J. drug Deliv. Sci. Technol.</source> <volume>32</volume>, <fpage>100</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2015.10.003</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xfc;ller</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Radtke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wissing</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations</article-title>. <source>Adv. drug Deliv. Rev.</source> <volume>54</volume>, <fpage>S131</fpage>&#x2013;<lpage>S155</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-409x(02)00118-7</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasrollahi</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Abbasian</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Farboud</surname>
<given-names>E. S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>
<italic>In vitro</italic> comparison of simple tretinoin-cream and cream loaded with tretinoin-SLN</article-title>. <source>J. Pharm. Technol. Drug Res.</source> <volume>2</volume> (<issue>1</issue>), <fpage>13</fpage>. <pub-id pub-id-type="doi">10.7243/2050-120x-2-13</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavicic</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gauglitz</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Lersch</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schwach-Abdellaoui</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Malle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Korting</surname>
<given-names>H. C.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment</article-title>. <source>J. drugs dermatology</source> <volume>10</volume> (<issue>9</issue>), <fpage>990</fpage>&#x2013;<lpage>1000</lpage>.</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phadtare</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Gaika</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Aher</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Formulation and characterization of nanoemulsion based nasal spray of azelastine hydrochloride</article-title>. <source>Res. J. Top. Cosmet. Sci.</source> <volume>7</volume> (<issue>2</issue>), <fpage>55</fpage>. <pub-id pub-id-type="doi">10.5958/2321-5844.2016.00009.1</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prow</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Grice</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Faye</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Nanoparticles and microparticles for skin drug delivery</article-title>. <source>Adv. drug Deliv. Rev.</source> <volume>63</volume> (<issue>6</issue>), <fpage>470</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2011.01.012</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raminelli</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Semreen</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Leonardi</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nanotechnological advances for cutaneous release of tretinoin: an approach to minimize side effects and improve therapeutic efficacy</article-title>. <source>Curr. Med. Chem.</source> <volume>25</volume> (<issue>31</issue>), <fpage>3703</fpage>&#x2013;<lpage>3718</lpage>. <pub-id pub-id-type="doi">10.2174/0929867325666180313110917</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reichling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Landvatter</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kostka</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>U. F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>
<italic>In vitro</italic> studies on release and human skin permeation of Australian tea tree oil (TTO) from topical formulations</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>64</volume> (<issue>2</issue>), <fpage>222</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2006.05.006</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riahi</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>P. R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Topical retinoids: therapeutic mechanisms in the treatment of photodamaged skin</article-title>. <source>Am. J. Clin. Dermatology.</source> <volume>17</volume> (<issue>3</issue>), <fpage>265</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1007/s40257-016-0185-5</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Ruther</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <source>Development and characterisation of a multi-layer patch with improved electrical stimulus transmission and self-regulating elastic properties for application in cardiac tissue engineering</source>. <publisher-name>Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg</publisher-name>.</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sch&#xe4;cke</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zollner</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>D&#xf6;cke</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Rehwinkel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jaroch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Skuballa</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases</article-title>. <source>Br. J. Pharmacol.</source> <volume>158</volume> (<issue>4</issue>), <fpage>1088</fpage>&#x2013;<lpage>1103</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00238.x</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sch&#xe4;fer-Korting</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mehnert</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Korting</surname>
<given-names>H.-C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Lipid nanoparticles for improved topical application of drugs for skin diseases</article-title>. <source>Adv. drug Deliv. Rev.</source> <volume>59</volume> (<issue>6</issue>), <fpage>427</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2007.04.006</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>M&#xfc;ller-Goymann</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>61</volume> (<issue>1-2</issue>), <fpage>77</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2005.03.006</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smirnova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Khizhnyak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pakhomov</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Film materials based on mixed aqueous solutions of poly (vinyl alcohol), simple amino acids, and silver nitrate</article-title>. <source>Fibre Chem.</source> <volume>54</volume> (<issue>6</issue>), <fpage>337</fpage>&#x2013;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1007/s10692-023-10404-y</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souto</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>R. H.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes</article-title>. <source>Drug. Delivery.</source>, <fpage>115</fpage>&#x2013;<lpage>141</lpage>.</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szyma&#x144;ski</surname>
<given-names>&#x141;.</given-names>
</name>
<name>
<surname>Skopek</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Palusi&#x144;ska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schenk</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stengel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lewicki</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Retinoic acid and its derivatives in skin</article-title>. <source>Cells</source> <volume>9</volume> (<issue>12</issue>), <fpage>2660</fpage>. <pub-id pub-id-type="doi">10.3390/cells9122660</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thakur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S. K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Thermosensitive injectable hydrogel containing carboplatin loaded nanoparticles: a dual approach for sustained and localized delivery with improved safety and therapeutic efficacy</article-title>. <source>J. drug Deliv. Sci. Technol.</source> <volume>58</volume>, <fpage>101817</fpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2020.101817</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trotta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Debernardi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Caputo</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Preparation of solid lipid nanoparticles by a solvent emulsification&#x2013;diffusion technique</article-title>. <source>Int. J. Pharm.</source> <volume>257</volume> (<issue>1-2</issue>), <fpage>153</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-5173(03)00135-2</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Application of electrospun drug-loaded nanofibers in cancer therapy</article-title>. <source>Polymers</source> <volume>16</volume> (<issue>4</issue>), <fpage>504</fpage>. <pub-id pub-id-type="doi">10.3390/polym16040504</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zasada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Budzisz</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments</article-title>. <source>Adv. Dermatology Allergology/Post&#x119;py Dermatologii i Alergologii</source> <volume>36</volume> (<issue>4</issue>), <fpage>392</fpage>&#x2013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.5114/ada.2019.87443</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Advances in lipid-based colloid systems as drug carrier for topic delivery</article-title>. <source>J. Control. Release</source> <volume>193</volume>, <fpage>90</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.05.054</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>DDSolver: an add-in program for modeling and comparison of drug dissolution profiles</article-title>. <source>AAPS J.</source> <volume>12</volume> (<issue>3</issue>), <fpage>263</fpage>&#x2013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-010-9185-1</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>